Empyrean Medical Systems, Inc.

What Empyrean Medical Systems, Inc. does

Empyrean Medical Systems, Inc. is a privately held Boca Raton, Florida-based radiation oncology company founded in 2012 to develop advanced medical devices, informatics, and therapeutics for cancer treatment. The company operates two core divisions — Research and Clinical Devices and Informatics — serving human cancer treatment centers, research institutions, veterinary oncology networks, and through a subsidiary, the biopharmaceutical market. Its product portfolio spans multiple platforms: MOVHEET (Magnetically Optimized Very High Energy Electron Therapy, licensed from MD Anderson Cancer Center, designed for both conventional and FLASH dose-rate delivery), the Morpheus beam sculpting system (acquired from Sensus Healthcare), Vektra (robotically-assisted brachytherapy/IORT, FDA 510(k) pending), Sirius PAWS-RT (veterinary radiation therapy), Artemis 320 (pre-clinical X-ray irradiator aligned with the federal CIRP program), and the OncoMatriX cloud informatics platform. A wholly-owned subsidiary, Empyrean Therapeutics, is developing the EMS-312 TLR-2 antagonist molecule for brain, pancreatic, breast, and other hard-to-treat cancers.

The underlying technology stack integrates quantum physics, high-temperature superconducting magnets (via MagCorp and MetOx), synthetic diamonds, molecular biology, robotics, Monte Carlo-based treatment planning, and machine learning for image-guided, computer-vision-enabled treatment. The company's intellectual property includes an exclusive MOVHEET license, the Fishman patent portfolio (10+ patents), Sculptura-acquired 3D Beam Sculpting IP, and EMS-312 patents granted in all major global markets. Empyrean's go-to-market combines direct enterprise sales to leading luminary cancer centers (including MD Anderson, with patient treatments anticipated to begin in 2026) with exclusive regional distribution — most notably Wide Code Industries Ltd. for Greater China (Mainland China, Hong Kong, Macau) — and a strategic veterinary channel through Thrive Pet Healthcare.

Revenue mechanics are diversified across three streams: capital equipment sales (MOVHEET, Morpheus, Vektra, Artemis, Sirius) targeted at hospital and research buyers; recurring subscription or service revenue through the OncoMatriX informatics platform for predictive maintenance and performance monitoring; and future licensing/royalty economics from the EMS-312 therapeutic pipeline. Key institutional shareholders include MD Anderson Cancer Center (15% stake) and Hamilton Reserve Bank (equity plus a $20 million credit line arranged January 2026), with Mayo Clinic also referenced as a co-shareholder. The company is currently pre-revenue, with commercialization scheduled to commence in 2026 and a planned 50,000–100,000 sq ft NeoCity manufacturing and engineering facility in Osceola County, Florida by early 2028.

Name

Empyrean Medical Systems, Inc.

Legal name

Empyrean Medical Systems, Inc.

Website

https://empyreanmed.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Empyrean Medical Systems is a Boca Raton-based radiation oncology company developing advanced devices — MOVHEET, Morpheus, Vektra, Sirius, and Artemis — and the OncoMatriX cloud informatics platform, serving cancer treatment centers, research institutions, and veterinary oncology markets through direct sales and regional distribution.

Ownership category

akta.pro rank

Product category

Radiation Oncology Medical Devices

NAICS

Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)

akta.pro secondary industries

Radiation Oncology (HLAKAFAC), Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)

Keywords

• Radiation oncology systems
• Medical device manufacturing
• Precision cancer treatment
• Radiotherapy equipment
• Clinical informatics platform

Headquarters

HQ city

Boca Raton

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Medical Device Sales: Sale of radiation oncology devices including MOVHEET system, Morpheus, Vektra, Artemis, and Sirius platforms. Product sales anticipated to begin in 2026 with revenue growth expected beyond.
2. Informatics Software/Services: Cloud-based OncoMatriX platform for performance monitoring, predictive maintenance, and data management. Subscription-based or service-based model for ongoing support and monitoring.
3. Therapeutic Development: Development and future commercialization of cancer therapeutic agents. EMS-312 TLR-2 antagonist molecule acquired from Eos Therapies targeting brain, pancreatic, breast, and other hard-to-treat cancers.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Empyrean Medical Systems designs, develops, and (anticipated for 2026) commercializes radiation oncology hardware systems and an AI-powered cloud informatics platform for cancer treatment and pre-clinical research. Its device portfolio includes MOVHEET very-high-energy electron therapy, Morpheus 3D Beam Sculpting systems, Vektra brachytherapy/IORT platform, Artemis 320 research X-ray irradiator, and Sirius veterinary radiation platform, complemented by the OncoMatriX cloud platform for performance monitoring and predictive maintenance. The company also advances a therapeutic pipeline through its subsidiary Empyrean Therapeutics (EMS-312 TLR-2 antagonist).

Product overview

Empyrean Medical Systems operates two core divisions: Research and Clinical Devices and Informatics. The Research and Clinical Devices division encompasses radiation oncology platforms including Artemis 320 (X-ray irradiator for pre-clinical research), Vektra (robotically-assisted brachytherapy/IORT system), Morpheus (beam sculpting radiotherapy), MOVHEET (magnetically optimized electron therapy), and Sirius (veterinary radiation platform). The Informatics division provides OncoMatriX, a cloud-based AI-powered platform for predictive maintenance and performance monitoring. Empyrean also maintains a therapeutic pipeline through Empyrean Therapeutics, including the EMS-312 TLR-2 antagonist molecule. The company integrates quantum physics, high-temperature superconductors, robotics, AI-driven treatment planning, and machine learning across its product portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• OncoMatriX: Cloud-based informatics platform that collects, organizes, and analyzes Artemis system performance data to support consistent operation and long-term stability.
• Artemis 320
• Vektra
• Sirius
• Morpheus
• MOVHEET

Products and services

• Artemis 320 X-ray Irradiator 320 kV research-grade X-ray irradiator purpose-built for researchers performing pre-clinical cell and small animal irradiation studies. Features automated operation, integrated AAPM TG-61 compliant dosimetry, programmable XYZ stage, dynamic four-jaw collimator, customizable filters/beds, high-resolution optical camera, Beam Eye View augmented reality imaging, and a high-resolution optical camera. Used by academic research institutions, pharmaceutical R&D labs, and contract research organizations needing standardized X-ray irradiation and cesium irradiator replacement.
• Vektra Brachytherapy/IORT Platform Cutting-edge robotically assisted platform for Brachytherapy and Intraoperative Radiotherapy (IORT). Features energy options of 50-120kV, patented beam sculpting/beam forming technology, precision robotic arm, integrated tomosynthesis imaging, FLASH capability (greater than 70 Gy/sec), minimal shielding requirements, and RespiraTrack respiratory motion tracking. Treats cancer patients intraoperatively in less than 20 minutes total workflow. FDA 510(k) clearance pending; not currently for sale.
• OncoMatriX Cloud Platform Cloud-based informatics platform that collects, organizes, and analyzes Artemis (and future clinical device) performance data. Leverages AI and machine learning algorithms for predictive maintenance, automated monitoring, anomaly detection, and seamless integration with Artemis research irradiators. Supports service planning, trend monitoring, and continuous improvement for radiation oncology devices.
• MOVHEET Radiation Therapy System MOVHEET (Magnetically Optimized Very High Energy Electron Therapy) uses magnetically optimized very-high-energy electron beams and x-ray photon beam sculpting to deliver radiation therapy with improved precision, cost, and efficacy. Designed to deliver both conventional and FLASH dose-rate radiotherapy for treating malignant tumors. Patented and exclusively licensed from MD Anderson Cancer Center; product sales anticipated to begin in 2026.
• Sirius Advanced Radiation Platform (PAWS-RT) Robotically accelerated conformal beam radiation platform combining robotic precision, Monte Carlo-based treatment planning, and real-time image guidance to deliver Photon Augmented Wave Stereotactic Radiation Therapy (PAWS-RT). Delivers highly targeted high-dose radiation while sparing healthy tissue and critical organs. FDA cleared for veterinary use, with first installation planned at Veterinary Specialty Center of Seattle via PetCure Oncology.
• Morpheus 3D Beam Sculpting Radiotherapy System Robotically-assisted beam sculpting image-guided radiotherapy system derived from the acquired Sculptura technology. Provides state-of-the-art Directional Anisotropic Radiation Therapy (ART) and brachytherapy using proprietary 3D Beam Sculpting technology for targeted cancer treatment during surgery or at the tumor site. FDA 510(k) cleared (originally as Sculptura in February 2019).
• EMS-312 TLR-2 Antagonist Therapeutic First-in-class novel small-molecule TLR-2 antagonist acquired from Eos Therapies for the treatment of brain, pancreatic, breast, and other hard-to-treat cancers. Being developed by Empyrean Therapeutics, Inc. in La Jolla, California. Currently in pre-IND phase, with patents granted in all major global markets in 2024.

Quantifiable outcome

• MOVHEET system designed to deliver both conventional and FLASH dose-rate radiotherapy (>70 Gy/sec) with enhanced precision
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability12 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered core, strategic, flagship and major acquisition.

• Wide Code Industries Ltd.coreChannel Partner/ Reseller/ Distributor · 5 February 2026Exclusive long-term commercial distribution agreement for Mainland China, Hong Kong, and Macau. Wide Code serves as exclusive commercial partner responsible for sales execution, channel development, market expansion, and future localization. Founded in 1990 with 30+ years of medical device sector experience in Greater China.
• Thrive Pet HealthcarecoreStrategic or Co-development Partner · 20 November 2025Strategic partnership to bring Sirius radiation platform to veterinary oncology. First installation planned for early 2026 at PetCure Oncology in Seattle. Thrive Pet Healthcare is one of the nation's leading veterinary networks with over 360 providers.
• PetCure OncologycoreStrategic or Co-development Partner · 20 November 2025First Sirius system installation at Veterinary Specialty Center of Seattle bringing human-grade precision radiation therapy to veterinary cancer care. Expanding access to life-saving treatment for pets in the Pacific Northwest.
• Concept CompaniesstrategicImplementation/ SI/ Consulting Partner · 16 December 2024Real estate developer for NeoCity facility project. Purpose-built facility development for Empyrean at NeoCity technology district. Project sized between 50,000 and 100,000 square feet. Concept specializes in science, technology, and healthcare real estate development.
• Eos Therapies, Inc.strategicTechnology or Integration · 25 October 2024Acquisition of first-in-class novel TLR-2 antagonist molecule (EMS-312) for development of cancer drug targeting brain, pancreatic, breast, and other hard-to-treat cancers. Transaction completed October 2024. IP, research data, and compound materials transitioned to Empyrean Therapeutics labs in La Jolla, CA.
• MagCorp Inc. (Magnetics Corporation)coreTechnology or Integration · 25 August 2023Strategic collaboration for large-scale development of novel radiation therapy technology. MagCorp provides superconducting magnet technology using MetOx's HTS wire. Team includes experts from National High Magnetic Field Laboratory. Key partner for NeoCity facility development.
• MetOx Technologies, Inc.coreTechnology or Integration · 25 August 2023Strategic collaboration for large-scale development of HTS (High-Temperature Superconducting) wire. MetOx is US leader in manufacturing HTS wire at scale using enhanced patented manufacturing process. Critical for enabling high magnetic fields required for radiation therapy technology.
• MD Anderson Cancer CenterflagshipStrategic or Co-development Partner · 10 August 2022Exclusive license and joint development agreement to advance novel technologies in radiation oncology and cancer therapeutics. Empyrean obtained exclusive license to develop and commercialize the MOVHEET method. MD Anderson receives equity interest and is eligible for royalties. MD Anderson holds 15% stake in Empyrean.
• Sensus Healthcare, Inc.major acquisitionOEM/ Whitelabel/ Licensing Partner · 25 February 2022Acquisition of Sculptura assets including inventory, systems, parts, and all related intellectual property for USD 15 million in cash. Sculptura provides targeted ART and brachytherapy utilizing proprietary 3D Beam Sculpting technology. Launched under Empyrean's Morpheus brand.
• Dynam.AIstrategicTechnology or Integration · 28 April 2021Strategic partnership for development of AI-driven products and platforms for advanced image processing, tumor detection, genomics analytics and simulation, and multi-modal tumor targeting and treatment. Dynam.AI designated as premier R&D partner providing computer vision and machine learning neural-network engines.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• ViewRay: Maker of the MRIdian MR-guided radiation therapy system. Comparable image-guided, precision radiation modality strategy targeting similar elite cancer center customers.
• Accuray: Developer of CyberKnife and TomoTherapy radiation therapy systems targeting both human and veterinary oncology. Competes with Empyrean's MOVHEET and Morpheus platforms in image-guided precision radiation delivery.
• Sensus Healthcare: Sculptura's prior owner and developer of superficial radiation therapy (SRT) systems. Directly comparable to Empyrean's Morpheus beam-sculpting ART franchise, given the asset acquisition history.
• Xstrahl: Specialist in small-animal and pre-clinical X-ray irradiators positioned in the CIRP Cesium replacement program. Direct competitor to Empyrean's Artemis 320 research irradiator.
• IntraOp Medical: Provider of IOERT (intraoperative electron radiation therapy) systems (Mobetron). Directly comparable to Empyrean's Vektra IORT/brachytherapy platform with overlapping clinical use cases.
• Mevion Medical Systems: Developer of compact proton therapy systems (MEVION S250i with HYPERSCAN). Comparable particle-therapy approach positioned between conventional RT and next-generation modalities like MOVHEET.

Emerging players

• RefleXion Medical: Developer of biology-guided radiation therapy (BgRT) for metastatic cancer. Comparable emerging-stage precision radiation oncology company pursuing novel physics-driven treatment paradigms.
• PetCure Oncology: National veterinary radiation therapy network currently deploying stereotactic radiosurgery. Now both a customer and potential competitor for Empyrean's Sirius platform in veterinary oncology.

Broad incumbents

• Varian Medical Systems (Siemens Healthineers): Global leader in conventional and proton-based radiation oncology (Halcyon, TrueBeam, ProBeam). Sets the competitive benchmark Empyrean's MOVHEET and Vektra platforms must displace.
• Elekta: Incumbent provider of linear accelerators (Versa HD, Elekta Unity MR-linac) and brachytherapy (Flexitron) solutions. Overlaps with Empyrean's MOVHEET, Vektra, and brachytherapy/ART portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/empyreanmed

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Empyrean Medical Systems, Inc.